| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5845705 | Pulmonary Pharmacology & Therapeutics | 2015 | 8 Pages |
Abstract
The systemic exposure to the active ingredients of a fixed dose combination of beclometasone/formoterol administered via pMDI with AeroChamber Plus⢠correlates with the nominal dose independently of patient age and body size. Thus, dose reduction in relation to age when using a pMDI with VHC may be unnecessary for reducing the systemic exposure in children.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Mirco Govoni, Annalisa Piccinno, Germano Lucci, Gianluigi Poli, Daniela Acerbi, Roberta Baronio, Dave Singh, Piotr Kuna, Bo L.K. Chawes, Hans Bisgaard,